Affordability of CGRP-targeted therapies and physician support for reimbursement in Southeast Asia and East Asia: a cross-country analysis from the SEALANT study
Year: 2026
Type: article
Abstract: Calcitonin gene-related peptide (CGRP)-targeted therapies have transformed migraine prevention, but access remains limited in many Southeast Asian countries because of cost and reimbursement barriers. We evaluated factors associated with physician support for reimbursement and examined the affordability of CGRP-targeted therapies across the region. This cross-sectional analysis used data from the South-East Asia Local breAch on MigraiNe Treatment (SEALANT) study, involving physicians’ perspective from Laos, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, and Thailand. Physicians were categorized according to support for reimbursement of CGRP-targeted therapies. Multivariable logistic regression identified factors associated with reimbursement support. Country-level analyses examined monthly treatment prices, affordability measured as minimum-wage working days required to purchase one month of treatment, and correlations between economic indicators and reimbursement support. Among 647 physicians, 474 (73.3%) supported reimbursement of CGRP-targeted therapies. Support was independently associated with perceiving CGRP-targeted therapies as effective (adjusted odds ratio [aOR] 5.76, 95% confidence interval [CI] 3.23–10.28), has minimal side-effects (aOR 3.78, 95% CI 2.27–6.32), recognizing migraine’s impact on quality of life (aOR 3.35, 95% CI 1.21–9.26) and productivity (aOR 2.08, 95% CI 1.24–3.50), introducing both acute and preventive therapies (aOR 2.48, 95% CI 1.28–4.82), and perceiving reimbursement barriers to treatment adherence (aOR 2.39, 95% CI 1.33–4.27). Physician demographics, practice setting, and national income classification were not independently associated with support. Median monthly treatment prices ranged from USD 301 in The Philippines to USD 380 in Indonesia and did not differ significantly across countries ( p = 0.949). In contrast, affordability varied markedly, ranging from 7.3 minimum-wage working days in Singapore to 50.9 days in Indonesia ( p = 0.001). Physician support for reimbursement was not associated with GDP per capita or affordability measures but showed a strong inverse correlation with local treatment price (Spearman’s ρ = −0.886, p = 0.019). Physician support for reimbursement of CGRP-targeted therapies in Southeast and East Asia was most strongly associated with perceptions of clinical value and migraine burden, rather than with national economic status. Despite broadly similar nominal prices, the minimum-wage-equivalent price burden varied substantially across countries, underscoring the importance of considering relative economic burden alongside nominal price when informing reimbursement and pricing decisions. Not applicable.
Source: The Journal of Headache and Pain
Authors: Wanakorn Rattanawong, Akarin Hiransuthikul, Supakorn Chansaengpetch, Prakit Anukoolwittaya, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Nijanth Manohararaj, Wan Aliaa Wan Sulaiman, Gerard Saranza, John Luis Wee, Greg Dayrit, Irma Savitri Madjid, Devi Ariani Sudibyo, Pepi Budianto, Jr-Wei Wu, Appasone Phoumindr, Chananchida Sirilertmekasakul, Surat Tanprawate, Stewart J. Tepper
Institutions: Chulalongkorn University, King Mongkut's Institute of Technology Ladkrabang, National Neuroscience Institute, Universiti Putra Malaysia, Philippine General Hospital, Cebu Institute of Medicine, Vicente Sotto Memorial Medical Center, Chong Hua Hospital, University of the Philippines Manila, St. Luke's Medical Center, University of Indonesia, Universitas Airlangga, Sebelas Maret University, National Yang Ming Chiao Tung University, University of Health Sciences Vientiane, Chiang Mai University, New England Institute for Neurology and Headache
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: CGRP-targeted therapy, migraine prophylaxis, drug affordability, reimbursement, physician attitudes, Southeast Asia, East Asia, financial barriers to treatment, medication adherence, GDP per capita, cost-effectiveness, pharmacoeconomics, quality of life, productivity loss, access to medicines
Open Access status: gold
Estimated APC paid: $3,990
OpenAlex ID: W7236234693
